WHY AFIRMA


Backed by rigorous evidence, Afirma helps you reduce overtreatment—and save the thyroid





Afirma Genomic Sequencing Classifier (GSC) reduces unnecessary thyroid surgeries

By reclassifying indeterminate thyroid nodules as benign, Afirma GSC can help reduce overtreatment


Afirma GSC provides answers from the first FNA biopsy

Efficient and timely results improve the patient’s experience


  • ADD GENOMICS TO THE FIRST FNA
    • Get answers faster2
    • Reduce worry and wait
    • Reduce cost6


  • The Veracyte Portal



    Results of Afirma genomic analysis are typically reported within 2 weeks through the portal, allowing physicians to manage and search electronic patient reports2
  • Reimbursement



    In-network and covered by most major payers—Afirma GSC is performed and billed only if the cytology result is indeterminate
Afirma benign results are durable with long-term follow-up

Operation rates in patients classified as benign with Afirma testing are comparable to those with benign results on cytopathology7,8


Only Afirma is proven reliable across 20+ studies




98.1%: NPV calculated as true negatives (Afirma GEC benign and either unoperated or operated and histopathologically benign) divided by all GEC benign results.
Xpression Atlas and Malignancy Classifiers


Prevent unnecessary surgery with Afirma GSC Xpression Atlas and Malignancy Classifiers


Xpression Atlas includes 761 variants and 130 fusions, identified through extensive literature review and categorized by level of clinical validation.

Risk stratify and expand genomic understanding with Xpression Atlas.

When necessary, the precision of Afirma Malignancy Classifiers may help you make an informed and highly individualized choice about surgery.



Xpression Atlas in the Afirma Diagnostic Flow

The Xpression Atlas Provides Additional Genomic Information among Cases Likely Headed to Surgery






1 Harrell RM, et al. AACE 2017. 2 Data On File. 3 Haugen BR, et al. Thyroid 2016. 4 NCCN Thyroid Carcinoma Clinical Practice Guidelines, v1.2017. 5 Patel KN, et al. WCTC 2017. 6 Li H, et al. JCEM 2011. 7 Singer J, et al. CMRO 2016. 8 Angell TE, et al. JCEM 2015. 9 Alexander EK, et al. NEJM 2012. 10 Harrell RM, et al. Endo Prac 2013. 11 Alexander EK, et al. JCEM 2014. 12 Lastra RR, et al. Cancer Cytopathol 2014. 13 McIver B, et al. JCEM 2014. 14 Sullivan PS, et al. Cancer Cytopathol 2014. 15 Celik B, et al. Diagn Cytopathol 2015. 16 Marti JL, et al. Ann Surg Oncol 2015. 17 Witt RL, et al. The Laryngoscope 2015. 18 Zhu QL, et al. Am J Roentgenol 2015. 19 Abeykoon JP, et al. Horm and Cancer 2016. 20 Chaudhary S, et al. Acta Cytologica 2016. 21 Dhingra JK, et al. Otolaryngol Head Neck Surg 2016. 22 Sacks WL, et al. Cancer Cytopathol 2016. 23 Samulski TD, et al. Diagn Cytopathol 2016. 24 Wu JX, et al. Thyroid 2016. 25 Yang SE, et al. Cancer Cytopathol 2016. 26 Al-Qurayshi Z, et al. JAMA Otolaryngol Head Neck Surg 2017. 27 Hang JF, et al. Cancer Cytopathol 2017. 28 Kay-Rivest E, et al. J Otolaryngol Head Neck Surg 2017. 29 Harrison G, et al. Arch Pathol Lab Med 2017. * 30,000 unnecessary thyroid surgeries avoided is calculated through Q2 2017. Statistics include Afirma GEC and the next-generation Afirma Genomic Sequencing Classifier.


Contact us today
Monday to Friday, 5:30 AM – 5:00 PM (PST)
Phone: 1.888.923.4762
International: +1.650.243.6335
Fax: 650.243.6388
support@veracyte.com